Ken Fisher’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$13.9M Buy
31,158
+5,940
+24% +$2.77M ﹤0.01% 360
2025
Q4
$11.4M Sell
25,218
-741
-3% -$319K ﹤0.01% 385
2025
Q3
$10.2M Buy
25,959
+204
+0.8% +$85.3K ﹤0.01% 406
2025
Q2
$11.5M Sell
25,755
-4,914
-16% -$2.26M ﹤0.01% 392
2025
Q1
$14.9M Buy
30,669
+761
+3% +$355K 0.01% 359
2024
Q4
$12M Buy
29,908
+2,886
+11% +$1.34M ﹤0.01% 411
2024
Q3
$12.6M Sell
27,022
-1,083
-4% -$520K 0.01% 392
2024
Q2
$13.2M Buy
28,105
+582
+2% +$253K 0.01% 391
2024
Q1
$11.5M Buy
27,523
+843
+3% +$356K 0.01% 402
2023
Q4
$10.9M Buy
26,680
+334
+1% +$123K 0.01% 398
2023
Q3
$9.16M Sell
26,346
-3,105
-11% -$1.09M 0.01% 444
2023
Q2
$10.4M Buy
29,451
+2,018
+7% +$680K 0.01% 448
2023
Q1
$8.64M Buy
27,433
+1,364
+5% +$409K 0.01% 474
2022
Q4
$7.53M Buy
26,069
+486
+2% +$148K 0.01% 489
2022
Q3
$7.41M Sell
25,583
-670
-3% -$193K 0.01% 430
2022
Q2
$7.4M Buy
26,253
+1,669
+7% +$447K 0.01% 381
2022
Q1
$6.42M Sell
24,584
-687
-3% -$163K ﹤0.01% 425
2021
Q4
$5.55M Buy
25,271
+1,157
+5% +$225K ﹤0.01% 448
2021
Q3
$4.37M Sell
24,114
-899
-4% -$176K ﹤0.01% 446
2021
Q2
$5.04M Sell
25,013
-1,040
-4% -$218K ﹤0.01% 431
2021
Q1
$5.6M Buy
26,053
+1,226
+5% +$269K ﹤0.01% 418
2020
Q4
$5.87M Buy
24,827
+353
+1% +$81K ﹤0.01% 401
2020
Q3
$6.66M Buy
24,474
+1,151
+5% +$318K 0.01% 374
2020
Q2
$6.77M Sell
23,323
-428
-2% -$116K 0.01% 365
2020
Q1
$5.65M Buy
23,751
+1,398
+6% +$321K 0.01% 344
2019
Q4
$4.89M Buy
22,353
+228
+1% +$46.1K ﹤0.01% 394
2019
Q3
$3.75M Buy
22,125
+276
+1% +$48.8K ﹤0.01% 465
2019
Q2
$4.01M Buy
21,849
+6,660
+44% +$1.16M ﹤0.01% 451
2019
Q1
$2.79M Buy
15,189
+12,768
+527% +$2.36M ﹤0.01% 483
2018
Q4
$401K Buy
2,421
+223
+10% +$38.6K ﹤0.01% 677
2018
Q3
$424K Buy
+2,198
New +$391K ﹤0.01% 674
2018
Q1
Sell
-5,089
Closed -$763K 828
2017
Q4
$763K Buy
5,089
+105
+2% +$15.5K ﹤0.01% 606
2017
Q3
$758K Sell
4,984
-962
-16% -$145K ﹤0.01% 589
2017
Q2
$766K Buy
5,946
+733
+14% +$88.2K ﹤0.01% 563
2017
Q1
$570K Buy
5,213
+45
+0.9% +$3.96K ﹤0.01% 549
2016
Q4
$381K Hold
5,168
﹤0.01% 596
2016
Q3
$451K Buy
5,168
+56
+1% +$5.29K ﹤0.01% 581
2016
Q2
$461K Sell
5,112
-43
-0.8% -$3.71K ﹤0.01% 568
2016
Q1
$421K Sell
5,155
-388
-7% -$35.1K ﹤0.01% 580
2015
Q4
$697K Buy
5,543
+615
+12% +$74.2K ﹤0.01% 542
2015
Q3
$513K Buy
4,928
+550
+13% +$70.7K ﹤0.01% 549
2015
Q2
$541K Sell
4,378
-8
-0.2% -$1.01K ﹤0.01% 447
2015
Q1
$517K Buy
4,386
+8
+0.2% +$959 ﹤0.01% 442
2014
Q4
$520K Sell
4,378
-215
-5% -$24.2K ﹤0.01% 448
2014
Q3
$516K Sell
4,593
-2,160
-32% -$206K ﹤0.01% 433
2014
Q2
$639K Buy
+6,753
New +$474K ﹤0.01% 416

Other funds holding VRTX

Ken Fisher's VRTX Position: Q1 2026 in Review

Ken Fisher increased its Vertex Pharmaceuticals (VRTX) stake by 24% in Q1 2026, buying an estimated $2.77M and bringing the position to 31,158 shares worth $13.9M. The position accounts for ﹤0.01% of the portfolio, ranked #360.

Ken Fisher first reported a position in VRTX in Q2 2014 and has held it in 46 quarters since. The position peaked at $14.9M in Q1 2025. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Ken Fisher held 31,158 shares of Vertex Pharmaceuticals worth $13.9M as of Q1 2026.
  • Ken Fisher bought 5,940 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.77M.
  • Vertex Pharmaceuticals made up ﹤0.01% of Ken Fisher's portfolio in Q1 2026, its #360 holding.
  • Ken Fisher first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 46 quarters since.
  • Ken Fisher's Vertex Pharmaceuticals position peaked at $14.9M in Q1 2025.
  • 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.